– March 1, 2014
March 1, 2014
View Issues
-
Second-line Docetaxel Improves Survival and Symptom Control in Advanced Esophagogastric Cancer
Patients with progressive advanced esophagogastric adenocarcinoma treated with docetaxel in addition to active symptom control (ASC) survived 44% longer than those who received ASC alone. -
Bendamustine-Bortezomib-Dexamethasone for Relapsed Myeloma
In a Phase 2 trial, Ludwig and colleagues present data on 79 patients with relapsed or refractory myeloma who were treated with bendamustine in combination with bortezomib and dexamethasone. -
Strategy to Overcome Rituximab Resistance in Patients with Indolent Lymphoma
In a Phase 2 study, Ahmadi and colleagues demonstrate reasonably high response rates in rituximab-resistant indolent lymphoma patients sequentially treated with lenalidomide/dexamethasone (Part 1; 2 monthly cycles) followed by lenalidomide/dexamethasone + weekly rituximab (Part 2; 3 monthly cycles). -
Toward More Effective Neoadjuvant Breast Cancer Therapy
In a Phase 3, randomized clinical trial of primary systemic therapy for patients with early, locally advanced breast cancer, the addition of capecitabine to each of six 3-weekly cycles of epirubicin-docetaxel resulted in a 1.64 fold increase in the possibility of primary tumor pathologic complete response. -
Cancer-reducing Effect of OCPs in BRCA1/BRCA2 Carriers: Do They Work?
The association between oral contraceptive use and ovarian or breast cancer in BRCA1 or BRCA2 mutation carriers are qualitatively similar to associations reported in the general population.